On June 1, 2026, Hanmi Pharmaceutical announced a licensing agreement with Eli Lilly for sonefpeglutide, a long-acting GLP-2 receptor agonist biologic candidate, in a deal valued at up to $1.26 billion. The agreement grants Lilly exclusive worldwide rights — excluding South Korea — for development, manufacturing, and commercialization of the drug for short bowel syndrome. Hanmi receives $75 million upfront with up to $1.185 billion in milestone payments tied to clinical development, regulatory approval, and commercialization.
The deal adds to a growing wave of biologics licensing transactions reshaping the global pharmaceutical supply chain. While GLP-1 agreements have dominated headlines, the Hanmi-Lilly deal highlights an important trend: major pharmaceutical companies are expanding biologics portfolios across multiple therapeutic modalities, and each new program creates fresh demand for CDMO partnerships and API manufacturing capacity.
Glucagon-like peptide 2 is a 33-amino-acid hormone that promotes intestinal growth and nutrient absorption. While GLP-1 has captured the spotlight for metabolic effects, GLP-2 agonists address a fundamentally different medical need: short bowel syndrome (SBS), a rare condition in which the intestine fails to absorb sufficient nutrients. SBS affects an estimated 40,000 patients in the United States and 200,000 globally, with treatment options historically limited to teduglutide (Gattex).
Hanmi's sonefpeglutide uses the company's LAPSCOVERY long-acting platform technology, conjugating the GLP-2 peptide with a fatty acid chain to extend half-life from approximately 2 hours to an estimated 48+ hours. This allows once-weekly or less frequent dosing — a significant improvement for patients who currently require daily injections. The regulatory pathway is well-defined, with sonefpeglutide having completed a global Phase 2 clinical trial in SBS.
The Hanmi-Lilly deal is part of a broader acceleration in biologics licensing activity defining 2026. In the first half of the year, China-origin biologics licensing deals have collectively exceeded $60 billion in total potential value — a pace tripled compared to 2025.
Key recent deals include BMS and Hengrui's $15.2 billion alliance across 13 oncology and immunology programs, Pfizer's $495 million ecnoglutide deal with Sciwind Biosciences, and Regeneron's expansion of its CytomX partnership to $4 billion for conditional bispecific antibodies. Each of these agreements requires manufacturing infrastructure — whether for peptide APIs, antibody production, or complex conjugation processes.
What makes the biologics licensing surge particularly significant for CDMOs is the diversity of modalities involved. Unlike small-molecule generics, where API manufacturing is standardized, biologics manufacturing requires specialized capabilities that vary dramatically between modalities. A CDMO equipped for monoclonal antibody production may lack expertise for peptide synthesis, ADC conjugation, or bispecific antibody engineering.
Global biologics CDMO capacity is already under pressure. Samsung Biologics reported record order inflows in Q1 2026, with utilization rates exceeding 90% across Korean facilities. The company's acquisition of GSK's Rockville, Maryland site represents a strategic bet that demand will continue to outstrip supply. WuXi Biologics' Singapore facility — designed to produce 100 million units of pre-filled syringes annually — is another response to the same demand signal.
For peptide-specific CDMOs, the pressure is more acute. The convergence of GLP-1 generic entry, oral GLP-1 formulation demand, and GLP-2 agonist development creates a multi-front strain on SPPS capacity. CordenPharma's recent acquisition of AmbioPharm — adding North Augusta, South Carolina and Shanghai manufacturing sites — creates a three-continent peptide manufacturing network spanning SPPS, LPPS, and hybrid synthesis at commercial scale.
But capacity expansion alone is insufficient. Biologics manufacturing requires analytical capabilities, stability testing infrastructure, and regulatory expertise across multiple jurisdictions. The WHO GMP certification bottleneck in India — where manufacturers like Neuland see 47% peptide API revenue growth but remain unable to serve regulated markets — illustrates the gap between raw capacity and qualified supply.
The Hanmi-Lilly deal creates specific opportunities for suppliers in the biologics value chain. Sonefpeglutide manufacturing requires not only the peptide API but also specialized conjugation chemistry for fatty acid attachment, purified drug substance for clinical supply, and eventually commercial-scale production.
For peptide API suppliers, the GLP-2 opportunity adds to surging demand from GLP-1 manufacturers. While volumes for a rare disease like SBS are smaller than for diabetes or obesity, pricing dynamics are favorable — rare disease APIs command premium prices due to lower volumes and higher quality requirements. Suppliers offering GMP-compliant GLP-2 peptide synthesis with validated conjugation processes will find willing buyers.
For intermediate suppliers, conjugation chemistry for long-acting peptides represents a growth opportunity. Fatty acid chain attachment — whether through direct acylation or linker-based conjugation — requires specialized reagents and purification steps. Companies supplying these intermediates at pharmaceutical grade will benefit from the expanding long-acting peptide market spanning GLP-1, GLP-2, and insulin analogs.
The Hanmi-Lilly deal reflects a structural shift in the pharmaceutical industry. Major innovators are building diversified biologics portfolios spanning multiple therapeutic modalities and targets. Each program — whether GLP-1, GLP-2, ADC, bispecific, or biosimilar — requires manufacturing partners with specialized capabilities.
For CDMOs and API suppliers, the implication is clear: the era of generalist manufacturing is ending. The winners will be those who develop deep expertise in specific modalities — peptide synthesis, antibody conjugation, oral formulation — and who can demonstrate the GMP compliance and supply chain resilience that innovators demand. The $60 billion wave of biologics licensing deals is not just creating revenue opportunities. It is redrawing the competitive map of pharmaceutical manufacturing.
